Swedish specialist pharmaceutical company Orexo has reported positive results from its Retrospective Evaluation of Zubsolv Outcomes A Longitudinal View (REZOLV) retrospective study of Zubsolv to treat opioid dependence.

Zubsolv is composed of buprenorphine and naloxone and formed as a sublingual tablet (CIII) to treat opioid dependence.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With an enrolment of 1,080 patients, the REZOLV was the largest retrospective study, completed last month in the US to optimise treatment of opioid dependence.

The study intended to determine the efficacy of Zubsolv in treating opioid dependence.

"The finalisation of the REZOLV study is one more important milestone we have reached during the summer."

Results validated the treatment efficacy of Zubsolv in reducing opioid dependence within 77.6% of the enrolled patients.

See Also:

Orexo president and CEO Nikolaj Sørensen said: “The finalisation of the REZOLV study is one more important milestone we have reached during the summer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In June we signed an ex-US license agreement with Mundipharma, followed by new legislation in the US with the potential to significantly improve access to treatment with Zubsolv and now we have finished the REZOLV study.

“We have seen a positive uptake in the use of Zubsolv in the US this summer, and with the REZOLV study we strengthen our ability to engage with physicians and payers in optimising and improving access to treatment of opioid dependence.”

The data generated from the study can aid the clinicians in the identification and rationalisation of some of the key factors related to a successful treatment of opioid dependence.